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This review reports on the role of laboratory confirmation and molecular epidemiology in global 
eradication of measles. The role of laboratory confirmation and molecular epidemiology in defining the 
origins of measles outbreaks cannot be overemphasized. New serological tests based on recombinant 
proteins detect only a fraction of the total measles virus (MV) specific antibodies. Several assays based 
on recombinant MV-haemagglutinin (ELISA and flow cytometry) or MV-fusion protein (flow cytometry) 
as well as neutralization and haemagglutination test have been evaluated using a large panel of low-
titre and negative sera. Isolation of measles virus confirmed the diagnosis. Phylogenetic trees are 
invaluable tools for monitoring the progress of immunization activities. Recent advances in genomic 
sequencing technology have lent its support to the monitoring and evaluation of vaccination 
programmes. More so, indigenous prepared measles antigens has been advocated to be produced, 
refined further and reproduced massively. This will be highly cost effective especially in field for 
seromonitoring and surveillance of measles. There is therefore, continual need for simpler diagnostic 
tests in elimination and eventual eradication of measles.  
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Measles is also one of the vaccine-preventable diseases 
(Washington State Department of Health, 2006) and 
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panded programme on immunization (EPI)-target 
diseases for eradication (WHO, 1998, 1999). It accounts 
for nearly half of the 1.7 million annual deaths due to 
childhood vaccine-preventable diseases (Baba et al., 
2007). The measles virus (MV) is monotypic and essen-
tially without animal reservoir (Norrby et al., 1975). As a 
result, measles control and eradication  should  be  within  










reach of aggressive surveillance and vaccination cam-
paign. Moreover, the virus is antigenically stable making 
the vaccine derived from the 1954 Edmonston isolate 
protective against all MVs (Rota et al., 1994a, b) and able 
to interrupt its transmission from infected to immune in-
dividuals. The industrialized nations of the world (for 
example, the United States) have used the live ate-
nuated MV vaccine to eradicate transmission of indige-
nous measles strains (Benenson, 1990). Before the intro-
duction of measles vaccines in the 1960s, almost every-
one contacted measles usually during childhood with an 
estimated 2.5 million death [mainly children] out of about 
130 million cases every year (Clements et al., 1992).  
Measles is endemic worldwide. Although it was 
declared eliminated from the U.S. in 2000, high rates of 
vaccination and good communication with persons who 
refuse vaccination is needed to prevent outbreaks and 
sustain the elimination of measles in the U.S (Parker et 
al., 2006). Of the 66 cases of measles reported in the 
U.S. in 2005, slightly over half were attributable to one 
unvaccinated individual who acquired measles during a 
visit to Romania (CDC, 2006a,b). This individual returned 
to a community with many unvaccinated children. The 
resulting outbreak infected 34 people, mostly children 
and virtually all unvaccinated; 9% were hospitalized and 
the cost of containing the outbreak was estimated at 
$167,685. A major epidemic was averted due to high 
rates of vaccination in the surrounding communities 
(Parker et al., 2006).  
Measles virus (MV) is the agent of acute illness called 
measles that has been reported as highly contagious and 
universal in occurrence. Measles produces significant 
illness, death and disability (Pan American Health 
Organization, 2005) and infects approximately 40 million 
people resulting in nearly 1 million deaths annually in 
developing countries (Oldstone, 1998). It has been 
reported as a major cause of childhood morbidity and 
mortality in Nigeria; 212,183 and 168,107 cases were 
recorded in 2000 and 2001 respectively (WHO, 2001).  





ienced 3,974 cases and 238 measles-deaths (Dubray et 
al., 2005). WHO, AFRO (2004) reported measles as one 
of the top five causes of death in children less than five 
years of age in many African countries. Measles disease 
is usually characterized by fever of 38°C or more; 
maculopapular rash of about 3 days or more; with one or 
a combination of coryza, cough, conjunctivitis and Koplik 
spots in the oral mucosa of measles’ victims (White and 
Fenner, 1994). It is spread through respiration (contact 
with fluids from an infected person's nose and mouth, 
either directly or through aerosol trans-mission) and is 
highly contagious, 90% of people without immunity 
sharing a house with an infected person will catch it. 
As measles can pose a significant threat to a person’s 
health, every effort should be made to arrest the indi-
genous transmission of measles in Nigeria. Measles 
elimination is defined as the interruption of indigenous 
measles virus transmission (that is, measles is no longer 
an endemic disease) in a large geographical area as a 
result of deliberate efforts. Continuing intervention is re-
quired while measles eradication is defined as the inter-
ruption of measles transmission worldwide as a result of 
deliberate efforts; intervention methods may no longer be 
needed. Eradication represents the sum of successful 
elimination efforts in all countries (WHO, 2000). There is 
continual need for simpler diagnostic tests in elimination 
and eventual eradication of measles. Therefore, this 
review reports on the role of laboratory confirmation and 




AETIOLOGY OF MEASLES DISEASE 
 
Measles is an acute viral illness that has been reported 
as highly contagious and universal in occurrence. It is 
caused by the measle virus (MV) (White and Fenner, 
1994). Measles virus (MV) is an enveloped virus belong-
ing to the genus morbillivirus of the family-paramyxovi-
ridae (Figure 1). It has a non-segmented, negative sense, 
single stranded RNA as its genome (White and Fenner, 
1994). The RNA genome contains 15,894 nucleotides 
encoding six structural and two nonstructural proteins. 
These are the nucleoprotein (N), phosphoprotein (P), 
matrix protein (M), fusion protein (F), haemagglutinin (H) 
and large polymerase (L). The nonstructural proteins V 
and C are derivatives of the viral P mRNA (Takeuchi et 
al., 2002).  
 
 
TRANSMISSION OF MEASLES VIRUS 
 
The highly contagious measles virus is spread by air-
borne droplets (circulating as a result of coughing and 
sneezing), close personal contact or direct contact with 
nasal or throat secretions of infected persons as well as 
through aerosols. Consequently, measles tends to occur 
as epidemics which may cause many  deaths,  especially  






Figure 2. Global Distribution of MV in WHO regions. Distribution of measles genotypes associated with endemic transmission 
in various areas of the world based on information available in 2002. Genotype designations are shown for each measles-




among young malnourished children. The virus remains 
active and contagious in the air or on infected surfaces 
for up to two hours. It can be transmitted by an infected 
individual from four days prior to the onset of the rash to 
four days after the onset. If one person has the disease, 
a high proportion of their susceptible close contacts will 
also become infected with the measles virus (WHO, 
2007).  
In densely populated areas, measles most commonly 
affect children aged 3 - 4 years old while in less crowded 
areas, highest incidence was among children aged 5 - 10 
years who contracted the disease on entering school 
(CDC, 2004a). Overcrowding in developing countries 
facilitates the ease of person-to-person transmission of 
the virus and increases the likelihood of exposure to high 
viral loads (Tulchinsky et al., 1993).  
In temperate climates, epidemics of measles tended  to  
occur at 2-5 years intervals and lasted 3-4 months. Gene-
rally, larger size of a community leads to a shorter 
interval between epidemics (WHO, 2007). Although there 
is only one serotype of MV, genetic variability exists in 
wild type viruses. WHO currently recognizes 23 geno-
types of MV (WHO, 2005) with 16 genotypes identified 
since 1990 (Figure 2). This variation however does not 
appear to be biologically significant as the vaccines avail-
able protect against them all (WHO, 2007).  
 
 
PEOPLE MOST AT RISK OF MEASLES DISEASE 
 
Un-immunized persons, especially young children, are at 
highest risk for measles and its complications, including 
death. Measles can also affect un-immunized older children, 
adolescents and young adults. All  people  who  have  not  










been immunized with vaccine or who have not acquired 
immunity through having experienced the disease can 
become infected. Measles can be particularly deadly in 
countries experiencing or recovering from war, civil strife 
or natural disasters. Infection rates soar because damage 
to infrastructure and health services interrupts routine 
immunization and overcrowding in camps for refugees 
and internally displaced persons greatly increase the risk 
of infection (WHO, 2007). 
It causes high mortality in poor populations, particularly 
among children less than 5 years of age. Case fatality 
rates in developing countries was estimated to vary 
between 2 - 6% and as high as 30% during outbreaks 
(Anon, 1989). Although other primate species may be 
infected through contact with human, no animal reservoir 
of measles virus has been identified (Albrecht et al., 
1977, 1980). Children and young adults do not usually 
die directly of measles, but from its complications such as 
pneumonia and diarrhea as a result of the immunosup-
pression associated with measles infection.  
 
 
IMMUNOLOGY OF MEASLES 
 
MV infection induces both humoral and cell mediated 
immunity (CMI) and provides a life long immunity 
(Bernstead et al., 1993). Primary infection induces high 
titres of IgM and IgG which can be detected in serum 
within few days of rash onset and specific secretory IgA 
antibodies in nasal specific secretions as illustrated in 
Figure 3 (Pringle and Heath, 1990; WHO, 2007). With 
sensitive IgM detection ELISA assays, 90% of measles 
cases are IgM positive at 3 days past rash onset (Triples 
et al., 2003). Serum and secretory IgA antibodies levels 





tion (Bernstead et al., 1993; WHO, 2007). Figure 2 shows 
the antibody response against measles.  
Re-exposure to MV induces a strong anamnestic 
immune response with a rapid boosting of IgG antibodies 
which prevents clinical disease(WHO, 2007), while 
waning antibodies are found in measles vaccines 
(Kremer et al., 2006), re-exposure to wild type virus have 
been found to stabilize specific IgG antibody levels in late 
convalescents (Kremer et al., 2006). Cytotoxic T cells 
and natural killer cells (NKC) which constitute cell 
mediated immunity plays a prominent role in immunity 
and recovery from acute infection. Patients with defective 
CMI often suffer severe progressive measles infections 
and have an increased risk of death (Pringle and Health, 
1990; WHO, 2007). Measles specific immune suppres-
sion begins with the onset of clinical disease, before the 
rash and continues for several weeks after apparent 
recovery (Redd et al., 1999). 
It is known that a one-dose one-time vaccination pro-
gramme may not be sufficient in conferring immunity 
against measles. Vaccine-induced protection has been 
well-documented to be less durable and less robust than 
naturally-acquired immunity against measles virus 
(Mossong and Muller, 2003) and high occurrence of 
symptomatic but mild measles due to secondary vaccine 
failures has been found among measles patients 
vaccinated over a decade ago, especially among those 
who were revaccinated (Paunio et al., 2000). Protection 
against measles could be incomplete as a result of 
vaccine failure (Mathias et al., 1989). Also, low vacci-
nations rates and limited number of related vaccine 
strains may subject the measles virus to considerable 
immunological pressure (Rota et al., 1994; Tamin et al., 
1994). Neutralization titre of any given serum measured 
by serological tests like neutralization test and heamag-
glutination inhibition assays (WHO, 2007) has been 
shown to correlate well with the degree of protection 
against MV (Rima et al., 1997). Titres of sera from human 
vaccines have been demonstrated to be lower against 
some wild type viruses than vaccine strains while sera 
from late convalescents neutralized both wild and vaccine 




LABORATORY ASSAYS AND DIAGNOSIS 
 
Availability of simple quantitative tests for the measure-
ment of measles neutralizing antibodies would be of 
considerable interest for vaccine related researches and 
to determine antibody levels of vaccines in the population 
(Ward et al., 1999). It is known that a one-dose one-time 
vaccination programme may not be sufficient in con-
ferring immunity against measles. This review summa-
rizes the importance of employing a simple laboratory 
test (haemagglutination inhibition assay) in determining 








Samples needed to be collected in most laboratories in-
clude blood, urine, saliva and throat swab, using appro-
priate materials. Lymphocytes have been isolated from 
whole blood at collection site. This and all other clinical 
samples had to be packed in ice-packs and be trans-
ported in an insulated vaccine container, to virology 





Other laboratory procedures needed to be carried out 
during any study include: 
 
1. Sample preparation 
2. Isolation of measles virus 
3. Storage of measles virus isolates and other clinical 
samples 
4. Detection of measles virus N and H genes 
5. Measles’ cDNA sequencing 





Lymphocyte isolation from whole blood 
 
In 2001, Amersham (the manufacturer of Ficoll-PaqueTM) 
described isolation of lymphocyte from whole blood. At 
room temperature, freshly drawn blood collected in 
EDTA-treated tube has to be mixed with minimum 
essential medium (MEM) in a clean plastic centrifuge 
tube while Ficoll-paqueTM has to be added to an empty 
centrifuge tube, then the diluted blood could be carefully 
layered without mixing. This tube has to be screw-capped 
and centrifuged at room temperature. The upper layer of 
centrifuged fluid has to be removed and the lymphocyte 
layer has to be also removed and dispensed into MEM. 
All samples should always be properly labeled to identify 





Most of the time, all urine specimen collected during any 
study has to be centrifuged 4°C to pellet the sediment 
(Papania et al., 2002). The supernatant has to be de-
canted and the pellet re-suspended in virus transport 
medium (VTM) (that is, 2% MEM plus antibiotics).  
 
 
The throat swabs  
 
WHO (AFRO) (2004) recommended that throat samples 
be placed in labeled virus  transport  swab  tube ensuring  




that the swab is immersed in the sponge containing the 
viral transport medium. One of the tubes has to be kept 
frozen and the other processed to isolate measles virus. 
 
 
The blood and saliva samples on filter paper 
 
There was enthusiasm for salivary antibody assays and 
other assays that did not require blood sampling. Viral 
RNA has been extracted from the isolated virus, as well 
as, filter-paper blood and saliva samples. It was also 
recommended that these samples be properly labeled 
and placed in separate plastic tubes. If further processing 
could not be done on arrival at laboratory, all samples 
should be stored at -20°C until use. 
 
 
Measles isolation  
 
Collection of viral samples for isolation and genotyping of 
measles virus is recommended to establish the genotype 
responsible for the case or outbreak. MV RNA could be 
extracted from isolated virus and filter-paper samples. 
The N and H genes could be subjected to RT-PCR. Pro-
ducts of the latter can be subsequently subjected to 
sequencing and phylogenetic analyses (Hanses et al., 
1999). However, clinical samples that test negative for 
measles virus isolation could be further tested for rubella 
and human B-19 parvovirus isolation. The clinical signs/ 
symptoms of the diseases caused by these two viruses 
were similar to measles’. 
 
 
MV isolation from lymphocytes 
 
Lymphocytes (fresh or freeze-thawed) have to be co-
cultured by inoculating 0.4 ml cell suspension, under 
biosafety cabinet (BSC) using semi-confluent monolayer 
of B95a cells and incubated at 37°C for 1 - 14 days. 
Presence of measles virus-specific cytopathic effects 
(CPE), that is, syncytium/giant cells indicates the pre-
sence of the virus. When the CPE has become 
advanced, the complete culture has to be harvested, 
aliquoted and stored in liquid nitrogen or at –20°C until it 
is used for RNA extraction (Hanses et al., 1999). Peri-
pheral lymphocytes of individuals with SSPE have been 
shown to contain MV (Fournier et al., 1985). Alternatively, 
the source of MV sequences may have been contami-
nated during autopsy (Simmonds et al., 2006). 
 
 
MV isolation from urine 
 
Urine sediment (fresh or freeze-thawed) has to be mixed 
with MEM and antibiotics. This have to be inoculated on 
semi-confluent monolayer of B95a cells (in 25 cm2 tissue 
culture flask) (Papania et al., 2002). Maintenance medium  




containing antibiotics has to be added after an hour of 
virus adsorption. If the CPE becomes advanced, the 
whole culture has to be harvested, pelleted by centri-
fugation and the pelleted cells should then be re-
suspended in MEM and kept frozen (-70oC). 
 
 
MV isolation from throat swab  
 
WHO (AFRO) (2004) also described that under BSC, 
swab will be broken and put in a vial containing 2 ml viral 
transport medium (VTM). The remaining fluid from the 
sponge in the transport tube will be pipetted and added to 
the vial. This will be screw-capped and kept at –20°C if 
not further processed immediately. The virus isolation will 
be done as described above. 
 
 
Serological detection of MV 
 
Haemagglutination inhibition test 
 
The Haemagglutinin (H) protein is an immunogenic trans-
membrane glycoprotein spike found on viral envelopes 
which is responsible for binding of virus to cells thereby 
playing important role in viral pathogenesis and immunity 
(Griffin, 2007). Antibody to H protein is measured by 
haemagglutination inhibition (HI) test which is relatively 
easy and inexpensive and has been of proven use in 
seroepidemiologic assays for viruses with H peplomer 
such as measles, influenza and rubella. They correlate 
strongly with level of protection against wild type viruses 
(Obi et al., 1996) and correspond to virus neutralization 
potential (Norrby et al., 1975). 
The HI test is the most widely acceptable test in most 
developing countries like Nigeria. Haemagglutination 
inhibition test has been used for a long time as a gold 
standard for laboratory diagnosis of measles infection 
(WHO, 2007). This is because, it is very sensitive and 
specific and easily performed in any laboratory. HI anti-
body test due to its easy and simple nature, has been an 
assay of choice in seromonitoring of protective level of 
immunity to measles virus in developing countries and 
the sole problem of non-availability of an highly potent HA 
antigen being faced in employing this test. Furthermore, 
recent studies have shown a considerable high level of 
protection against measles among youths. It was how-
ever reported in recent studies, that cases of unprotected 
young individuals against measles are still present in 
Nigerian population, which is an indication that our 
vaccination campaigns in this country needs to be inten-
sified and properly evaluated to improve on the succes-
ses and correct the faults. It was also further indicated in 
a study by Motayo, (2007) and Ogundiji, (2008) that sub-
tle genetic changes in the RNA genome of measles virus 
is translating into increase in virulence thereby posing a 





Enzyme-linked immunoassay (ELISA) test  
 
The ELISA is another sensitive test which is also used for 
diagnosis of measles virus infection but it is more 
expensive and requires the use of special equipment not 
found in many laboratories in developing countries like 
Nigeria (WHO, 2007). To standardize testing and control 
costs, PAHO elected to use a single ELISA test kit in 
national laboratories throughout the region and to rely on 
several specialized reference laboratories to conduct 





Formalin fixed, paraffin embedded tissues should be 
analysed by immunohistochemistry. The method used by 
McQuaid et al. (1990) should be modified as the case 
may be. Simmonds et al. (2006) modified McQuaid et al. 
(1990) method as follows: Formalin fixed, paraffin em-
bedded 7 m thick tissue sections on silane-coated slides 
were hydrated in xylene and alcohol. Endogenous pero-
xidase activity was blocked by 10 min incubation in 3% 
H2O2 in methanol. Tissues were washed in water and 
blocked in blocking solution (1:20 dilution of normal rabbit 
serum in PBS-T (0.1% Tween-20 in PBS)) for 10 min. 
Sections were incubated with a monoclonal mouse anti-
bodies against the N protein (clone 7C11, (Samuel et al., 
2003) at a dilution of 1:2000 in blocking solution overnight 
at 4°C, washed in PBS-T and incubated with a biotin 
conjugated secondary antibody (Dako, UK) at 1:400 in 
blocking solution for 1 h. After further washing, strepta-
vidin coupled HRP (Dako, UK) was added for 30 min, 






Tissues should be homogenized in lysis buffer (50 mM 
Tris, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1% Triton 
X-100. Protease inhibitors should also be added) and 
protein concentrations of whole lysates, without removal 
of cell debris, should be determined by spectrophoto-
metry. Equal amounts of total protein of each sample 
should be analyzed by SDS-PAGE and immunoblotting. 
The 7C11 MV N specific antibody has been used to 
probe blots, which should be followed by detection with 
an anti-mouse-HRP antibody (Dako, UK) and ECL plus 
reagents (Amersham Bioscience, UK, 2001) as described 
by Simmonds et al. (2006). 
 
 
Genotypic study and phylogenetic analyses 
 
For detection, the measles virus nucleoprotein and hae-





Tissues should be homogenised and total RNA extracted 
with RNeasy Mini kit (Qiagen, UK) or any other standard 
kit. RNA should be treated with DNase to avoid amplify-
cation of genomic DNA. The concentration of extracted 
RNA should be determined by spectrophotometry and the 
desired quantity of RNA should be reverse transcribed 
using random primers. PCR primers should be designed 
using Primer3 software (Rozen and Skaletsky, 2000) to 
yield a desired base pair amplification fragments such as 
192, 223, 206, 238, 234 and 218 base pair amplification 
fragment of MV N, M or H gene, human GAPDH, beta-
actin and 18S rRNA, respectively and where possible, it 
should be read across intron/exon junctions to avoid 
amplification of genomic DNA (Simmonds et al., 2006). 
The cDNA product obtained from the latter should be 
subjected to comparative sequence and phylogenetic 
analyses in order to assign cladetypes and genotypes to 
the virus isolates. The genetic diversity of all isolates and 
influence of measles vaccination on measles virus 
genetic evolution, among others, have been reviewed. To 
investigate a possible link between virus integrity and 
viral spread, MV loads detected should be compared with 
the extent of MV M gene and protein mutation reported 
previously (Kuhne et al., 2005). Increased MV RNA levels 
per cell may indicate a more actively replicating virus, 
which may causes faster progressing disease. Alterna-
tively, infection of a greater number of cells may lead to 
destruction of more tissue, which may also lead to 
accelerated disease. In summary, the amount of MV 
protein and RNA differs greatly in different cases of 
SSPE, which may influence progresssion of the disease. 
Further studies of greater numbers of cases are required 
to confirm any findings (Simmonds et al., 2006). 
 
 
MV nucleic acid sequencing 
 
De Swart et al. (2001) described the extraction of viral 
RNA from the blood and saliva on filter paper using high 
pure viral nucleic acid isolation kit. Total viral RNA could 
also be extracted from stored MV using guanidinium-acid 
phenol method (Chomczynski and Sacchi, 1987). Briefly, 
the virus has to be incubated with Trizol and viral RNA 
extracted with chloroform and precipitated with isopro-
panol. The extracted MV N and H mRNA has to be used 
to synthesize the required and respective cDNAs using 
RT-PCR with appropriate primers (Hanses et al., 1999). 
The RT-PCR products have to be purified in 1% agarose 
gel electrophoresis. The amplicons should then be 
directly sequenced with the dye terminator cycle sequen-
cing kit using appropriate primers. As MV can usually be 
detected in brain tissue from biopsy or autopsy by RT-
PCR and/or immunohistochemistry, it is thought to persist 
and spread within the CNS. Although the brain appears 
to be the main location of persistent MV in SSPE, it is not 
entirely clear if this is also the site of persistence and the 
only target during disease. Viral antigen or RNA has been  




detected outside the CNS in SSPE cases (Fournier et al., 
1986; Jin et al., 2002). To address the question of MV 
persistence outside the CNS in SSPE, Simmonds et al. 
(2006) included available peripheral tissues of two SSPE 
patients in their analysis on measles viral load which may 





The sequence data are usually analyzed using the 
CLUSTAL X software (Thompson et al., 1994) for multi-
ple sequence alignments. A PHYLIP package has also 
been used for the phylogenetic analysis in order to assign 
the MV isolates clades and genotypes (Felsenstein, 
1993). The dendrogram showing the genetic relationship 
of the isolates with the reference sequence has been 
provided. All the isolates, genotypes and clades could be 






Viral load has been correlated to disease development, 
progression and outcome in several infections, including 
HIV, SIV, cytomegalovirus (Bowen et al., 1996; Gor et al., 
1998) and Epstein-Barr virus (Kimura et al., 2002). 
Occurrence of cognitive impairment in HIV infected 
patients and development of SIV encephalitis in maca-
ques was linked to the level of viral RNA in the cerebro-
spinal fluid (CSF). In contrast, CNS disease did not 
correlate with plasma viral load in either HIV or SIV (Ellis 
et al., 1997; McArthur et al., 1997; Zink et al., 1999). With 
the exception of the study by Simmonds et al. (2006), no 
studies have been carried out so far trying to relate the 
progression of SSPE with viral load. Due to the rarity of 
the condition and the invasiveness of removing biopsy 
samples, obtaining information on viral load during the 
course of disease is problematic. However, the use of 
autopsy samples may provide some insight into this 
relationship (Simmonds et al., 2006). 
 
 
THE ROLE OF LABORATORY CONFIRMATION IN 
MEASLES ERADICATION 
 
In 1994, countries in the WHO region of the Americas set 
themselves the goal of interrupting the transmission of 
endemic measles by the end of 2000 using strategies 
developed by the Pan American Health Organization 
(PAHO, 1995). These strategies included recommenda-
tions for vaccination activities intended to achieve high 
population immunity together with sensitive surveillance 
for suspected measles cases and effective virological and 
serological surveillance (de Quadros et al., 1996). In the 
Americas, a suspected measles case  is  defined  as  any  




individual with a febrile rash illness (de Quadros et al., 
1996). Since 21 November 2002, no endemic measles 
transmission has been reported in Latin America (PAHO, 
2003a, b).  
Most strategies for reducing global measles morbidity 
and mortality and eliminating measles are based on the 
ability to enhance immune responses to measles virus 
(Moss and Polack, 2001). During the WHO campaign on 
the eradication of measles, accurate discrimination bet-
ween immune and non-immune individuals became 
increasingly important. Due to waning immunity in 
vaccinated population, the performance of a measles IgG 
assay depends mainly on its ability to detect reliably 
seronegative individuals among many vaccinees with low 
antibody levels. New serological tests based on 
recombinant proteins detect only a fraction of the total 
measles virus (MV) specific antibodies. Therefore, seve-
ral assays based on recombinant MV-haemagglutinin 
(ELISA and flow cytometry) or MV-fusion protein (flow 
cytometry) as well as neutralization and haemag-
glutination test have been evaluated using a large panel 
of low-titre and negative sera (Hartter et al., 2000).  
Isolation of measles virus confirms the diagnosis. A viral 
specimen can be evaluated for the presence of measles 
virus by PCR in a specialized network laboratory if culture 
attempts fail. Moreover, the molecular analysis of the 
virus may be essential to confirm its source (Dietz et al., 
2004).  
A key component of the programme has been a 
laboratory network, established in 1995, comprising 22 
national laboratories, 10 of which function as reference 
centres, and three as specialized reference laboratories 
(Venczel et al., 2003). National laboratories were respon-
sible for the testing of blood samples for immunoglobulin 
M (IgM) antibodies. A case is confirmed serologically, 
virologically or by epidemiological linkage to another con-
firmed case. Commercially available enzyme immuno-
assay (EIA) kits for IgM-class antibodies are currently in 
use throughout the region and all network laboratories 
use the same test kit (Ozanne and d’Halewyn, 1992). 
PAHO recommends that blood sample be taken at the 
first contact with a suspected case and within 30 days of 
onset of rash. The test kits in use have been shown to 
have high sensitivity and specificity. However, cross-
reactions with other viral diseases, e.g. rubella and 
Parvovirus, may occur (Thomas et al., 1999; Ratnam et 
al., 1995). 
As seen in Figure 3, if the first serum sample is found 
to have IgG antibodies, but IgG titres in the second 
sample show no change when compared to the first 
sample, the case would not be considered measles and 
could be discarded. The IgM-positive test result would be 
considered a false-positive. However, if the second 
sample shows a fourfold higher IgG antibody titre than 
the first sample, the case should be considered an acute 
measles infection and confirmed (Dietz et al., 2004). If 





less than fourfold higher than in the first sample, it would 
not be possible to determine whether or not it was an 
acute infection. Thus, no conclusion could be reached as 
to the actual status of the suspected case. In this situa-
tion, for programmatic considerations, the suspect case 
should be confirmed solely on the basis of the positive 
IgM test result. For the purposes of elimination program-
mes, it is better to incorrectly confirm a non-case than to 
discard a true measles infection (Dietz et al., 2004). If 
both the first and second samples are negative for IgG 
antibodies, the case would not be considered to be 
measles and should be discarded. If, however, the 
second sample is IgG-positive for measles, the case 
should be confirmed as acute measles infection (Dietz et 
al., 2004). Sometimes, there may be an insufficient 
volume from the first sample for IgG antibody testing, but 
a second sample would still be required. If the second 
sample is negative for IgG, the case should be discarded. 
If, however, the second sample is IgG-positive, it would 
not be possible either to confirm or discard the case, 
because the positive result could represent an acute or 
past infection. In such a situation, the case must be 
confirmed based on the IgM test result. Regardless of the 
scenario or testing sequence results, when in doubt, the 
case should be confirmed on the basis of the positive IgM 
test result (Dietz et al., 2004). 
No laboratory test is 100% sensitive or specific and 
false-positive results of laboratory tests do occur (Dietz et 
al., 2004). The positive predictive value of a laboratory 
test decreases as the prevalence of the disease de-
creases resulting in an increase in the number of false-
positive results (Mausner and Kramer, 1985). Therefore, 
as progress towards elimination is made, that is, as the 
prevalence dramatically decreases, some false-positive 
laboratory results should be expected. In countries that 
maintain high levels of vaccination activity and of surveil-
lance for rash and fever, the notification of febrile rash ill-
ness in recently vaccinated persons should be antici-
pated. This is an important consideration because at 
least 5% of primary vaccinations can result in a febrile 
rash illness (CDC, 2002). Thus, epidemiologists and 
managers of measles elimination programmes must be 
prepared to interpret a positive IgM laboratory test in the 
setting of greatly reduced disease, or when the clinical 
and epidemiological data indicate that the case in 
question is not measles (Dietz et al., 2004). In such situa-
tions, the dilemma is to determine whether a measles 
IgM-positive result occurs because: 1) the subject has an 
acute measles infection; 2) the test result is a false-
positive, or 3) the subject was recently vaccinated against 
measles. 
Despite active surveillance, there has been no evi-
dence of an extended chain of measles transmission 
among individuals infected in most country, for instance, 
United States where measles is no longer endemic 
(MMWR, 2002). However, the elimination of endemic 





cases. As long as measles circulates in other countries, 
measles will be imported into the United States (CDC, 
2004b). The possibility of transmission to susceptible con-
tacts mandates a commitment to high rates of immuni-
zation, active surveillance with rapid diagnosis to prevent 
the reestablishment of endemic measles (Meissner et al., 
2004).  
Laboratory findings comprise only part of the process 
used to determine whether a suspected measles case is 
a true case. Test results are affected by the quality of 
samples received, inherent limitations of the test because 
of the low prevalence of measles and the technical 
expertise of the laboratory staff conducting the tests 
(Dietz et al., 2004). In addition, when a sample is taken 
within 3 days of onset of rash, up to 30% of true measles 
infections may be IgM-negative (Helfand et al., 1997). 
The proficiency of the laboratory performance can be 
assured through site visits, exchange of samples for re-
testing and participation in annual proficiency testing 
(Venczel et al., 2003). 
Vaccination of susceptible individuals through the full 
implementation of the strategy recommended by PAHO 
in all countries remains the foundation of the regional 
measles elimination initiative (de Quadros et al., 2003). 
Until programmes for measles elimination are imple-
mented worldwide, importations will continue to occur in 
the Americas. Sensitive measles surveillance and high 
population immunity must be maintained to prevent the 
resumption of endemic transmission. Laboratory surveil-
lance remains a central activity within the elimination pro-
gramme (Cutts and Brown, 1995). Standardized approa-
ches to laboratory testing and interpretation of results are 
critical to ensure the continued success of the program-
me (Dietz et al., 2004).  
 
 
THE ROLE OF MOLECULAR EPIDEMIOLOGY IN 
MEASLES ERADICATION 
 
Molecular epidemiology of MV entails genetic charac-
terization of the wild-type (wt) virus and it is an important 
component of measles surveillance (WHO, 2003). Mea-
sles surveillance and epidemiological investigation is able 
to identify the source and transmission pathways of the 
virus. This is most beneficial when the change in viral 
genotypes over time in a particular region can be ob-
served, because the information from the genetic 
analyses can document the interruption of transmission 
of endemic measles. Consequently, molecular characteri-
zation of wt MVs has become a valuable tool for the 
evaluation of the effectiveness of measles control and 
elimination programmes. WHO therefore recommended 
that viral surveillance is conducted during all phases of 
measles control and that virological activities be expan-
ded to provide an accurate description of the global distri-
bution of measles genotypes.  
In line with the above, WHO published guidelines  for  a  




uniform nomenclature for designating wt MVs and descri-
bing genotypes (WHO, 2003). The guidelines include the 
laboratory methods used for genetic characterization. It 
also stated that the minimum amount of data required for 
determining the genotype of a MV is the sequence of the 
hypervariable 450 nucleotides (nt) that code for the 
carboxyl terminal 150 amino acids of the viral nucleo-
protein (N). These sequence data can be obtained from a 
viral isolate or by amplification of MV sequence directly 
from RNA extracted from a clinical specimen. When a 
new genotype is suspected, in addition to N sequence, 
complete H gene (1854 nts) sequence should always be 
obtained. WHO established standard reference sequence 
with which the nt sequence of MV isolates should be 
compared. New genotypes that were identified as a result 
of expanded virological surveillance made WHO (2001) 
update the virus nomenclature to cater for new MV geno-
types. New genotypes are suspected and designated if 
the nt sequence differs from the closest reference 
sequence by more than 2.5% in N and 2.0% in H. 
Proposed new genotypes should be assigned lower case 
letter (e.g. g3). 
MV genetic characterization essentially includes clade-
typing, genotyping and phylogenetic analysis. The terms 
clade and genotype are used to describe the genetic 
characteristics of wt MVs. For the purpose of molecular 
epidemiology, the genotype designation is the operational 
taxonomic unit, while the clades indicate the genetic 
relationship between the various genotypes. Currently, 
there are eight clades (A-H) which have been divided into 
22 genotypes and one proposed genotype (i.e. d10) 
making 23 genotypes recognized by WHO. Clades B, C, 
D, G, and H each contain multiple genotypes (B1-3; C1-
2; D1-10; G1-3; H1-2) while clades A, E and F each 
contain a single genotype (WHO, 2001; 2003). The nt 
sequences of the MV vaccine strains indicated that the wt 
viruses from which they were derived were all members 
of genotype A. 
Since molecular epidemiology has permitted different 
MV isolate to be grouped into clades and genotypes, the 
major group which has been identified indigenous to 
Africa, is clade B. In Nigeria, a measles endemic nation, 
the first genotyping and phylogenetic characterization of 
circulating MV revealed that the viruses were in clade B 
genotype 3 (B3) (Hanses et al., 1999). However, the MVs 
studied then were from Ghana and Nigeria of which the 
Nigerian isolates were exclusively from south-western 
Nigeria, precisely from Lagos and Ibadan. Another 2002 
report identified two MVs belonging to B3.1 genotype 
circulating from Sudan to Nigeria and Ghana and to 
Cameroon, whereas the B3.2 genotype was said to be 
found in West Africa (Kouomou et al., 2002). 
However, recent molecular epidemiologic studies have 
demonstrated interruption of circulation of genotype D6 
viruses that were responsible for the large measles out-
break in Sa˜o Paulo in 1997 and subsequent outbreaks in 
Rio de Janeiro, Argentina,  Chile,  Bolivia,  Haiti,  and  the  




Dominican Republic (Canepa et al., 2000; Oliveira et al., 
2002). The recorded low number of cases and the identi-
fication of genotypes other than D6 in association with 
measles cases imported into South and Central America 
are consistent with regional elimination (PAHO, 2001; 
Hersh et al., 2000; CDC, 2000a, b). 
In 1998, WHO published guidelines for a uniform 
nomenclature for designating wild type measles viruses 
and describing genotypes thereby providing guidelines 
for laboratory methods used for genetic characterization 
(WHO, 2007b). In 2001, 2003 and 2005, World Health 
Organization (WHO) recommendations were updated to 
take into account the identification of new genotypes 
resulting from expanded virological surveillance (WHO, 
1998, 1999, 2001, 2002, 2003, 2005, 2007b). Molecular 
epidemiology of MVs is an important component of 
measles surveillance as it provides a method for identi-
fying the geographical origin and tracing transmission 
pathways of a virus (WHO, 2007b). Two measles strain 
banks, the MV section of the Center for Disease Control 
and Prevention (CDC) USA and the Health Protection 
Agency (HPA) UK, have been designated by WHO to 
acquire, analyze, store and dispense representative 
strains (WHO, 2007b). The terms clade and genotype are 
used to describe genetic characteristics of wild type MVs.  
For molecular epidemiological purposes, the genotype 
desig-nations are the operational taxonomic unit while 
clades are used to indicate genetic relationship between 
the various genotypes. Altogether, eight Clades are re-
cognized designated A-H, within the Clades 23 geno-
types. With the exception of genotype F, all of the geno-
types have a corresponding references strain (WHO, 
2007b). Many laboratory networks have used various 
molecular approaches and epidemiology to:  
 
1. Determine the source of imported viruses  
2. Follow the pathway of virus circulation  
3. Monitor the progress or lack of progress of the vac-
cination programme 
4. Identify reservoirs sustaining virus circulation 
5. Detect gaps in surveillance; and  
6. Show geographical distribution of the virus. 
 
 
CURRENT TRENDS   
 
In 1991, a measles outbreak occurred in Fukuoka, Japan, 
in which Hidaka et al. (1994) observed 15 cases of mea-
sles vaccine failure (MVF). However, the introduction of 
enhanced diagnostic tests for IgM detection such as IgM-
capture EIA, with results which may be positive for 
patients with measles reinfection due to secondary vac-
cine failure, has highlighted the difficulty in differentiating 
between primary infection or reinfection due to primary 
and secondary vaccine failure (Erdman et al., 1993; 
Hidaka et al., 1994; Helfand et al., 1997; Paunio et al., 





secondary vaccine failure is probably more common than 
suggested by studies relying on specific IgM (Paunio et 
al., 2000), because measles-specific IgM is also inducible 
by reinfection (Erdman et al., 1993). The estimation of 
IgG antibody avidity is useful for identifying primary and 
secondary immune responses, but there have been few 
reports of its use during measles outbreaks (Pannuti et 
al., 2004). The results of the study by Hamkar et al. 
(2006), which showed that 18.4% of 365 measles cases 
confirmed by a positive IgM test mounted a secondary 
immune response, provide further evidence that the 
presence of IgM cannot be used as a reliable indicator of 
a primary immune response (Pannuti et al., 2004). 
However, while many developed countries have suc-
cessfully controlled measles and are currently in measles 
elimination and eradication phase (CDC, 2005); Nigeria, 
in tune with global goal, is just on measles control goal 
(that is, morbidity and mortality reduction). As a result, it 
recently concluded a nationwide accelerated measles 
vaccination campaign in June /July, 2006. Measles as 
one of the leading cause of childhood morbidity and mor-
tality and the need to effectively monitor through active 
surivellance, control and eventually eradicate measles 
cannot be overemphasized.  
Where relatively extensive virologic surveillance has 
occurred, two general patterns of measles genotype 
distribution have been observed. Figure 3 shows the 
global distribution of MV in WHO regions. In countries 
that still have endemic transmission of measles, most 
cases are caused by relatively few endemic genotypes. 
In countries that have eliminated measles, the small num-
bers of cases are caused by a number of different geno-
types that reflect various imported sources of virus and 
suggest the lack of sustained transmission of an endemic 
genotype (Rota and Bellini, 2003).  
Recent advances in genomic sequencing technology 
have lent its support to the monitoring and evaluation of 
vaccination programmes. Phylogenetic trees are invalu-
able tools for monitoring the progress of immunization 
activities. Viruses of the same genetic lineages cluster 
geographically together in a phylogenetic tree (Adu, 
2008). In a study, Nigerian measles isolates was classi-
fied into Cluster I and II of a newly discovered B3 
genotype of Clade B (Hanses et al., 1999). According to 
Adu (2008) before 1999, no field isolate of the measles 
virus from Nigeria had ever been studied and that study 
put Ibadan and Nigeria in general, in the measles 
epidemiological map of the world for the first time. 
According to Adu (2008), these efforts are with ultimate 
aim of detecting the viruses and the un-immunized 
children and of reaching every Nigerian child with the 
vaccine in order to stop the unnecessary suffering and 
untimely death resulting from these vaccine preventable 
diseases.  
Maintenance of high routine vaccination coverage and 
community-based surveillance (that is, case identification, 





and equipped primary health-care personnel. Strengt-
hening the primary health-care system and EPI in deve-
loping countries, although perhaps not essential for inter-
ruption of measles virus transmission, greatly facilitates 
achieving and maintaining measles elimination in a 





Often, identification of vaccine virus from a sample 
collected from an individual presented with rash after 
vaccination has provided the evidence necessary for 
classification of the case as vaccine-associated. Although 
facilities for both virus isolation and direct detection of 
measles virus by reverse transcription followed by the 
polymerase chain reaction (RT-PCR) are available in 
certain regional reference and specialized laboratories, 
only serological confirmation is performed in all national 
laboratories. Viral samples have limited utility in the net-
work for case confirmation because negative results may 
result from poor quality of the sample and therefore 
cannot be used to rule out a suspected case. Thus, RT-
PCR has not been utilized at the country level throughout 
the region (Dietz et al., 2004). 
The HA/HI test is not only relevant in the diagnosis of 
measles infection but is also very important for 
seromonitoring of measles infection. A readily available 
measles HA antigen will be a very valuable and useful 
tool for monitoring the progress of measles serocon-
version following immunization in Nigeria. To perform the 
HA/HI test, a potent measles antigen is therefore needed. 
Up till now, this measles antigen is still being imported at 
very expensive amount into Nigeria. Also to import the 
foreign brands of this measles antigen into Nigeria takes 
a very long time and often a time, they arrive having lost 
their potency or very close to their expiry date. There 
have been previous attempts to produce indigenous 
available measles antigen in Nigeria laboratory by 
sonication which had not been too successful because of 
the very low titre of the antigen (Adu Personal 
Communciation, 2007; Motayo, 2007). The indigenous 
prepared measles antigen has also been advocated to be 
produced, refined further and then massively produced. 
This will be highly cost effective especially in field for 
seromonitoring and surveillance of measles. 
Critical therefore to measles surveillance is the mole-
cular characterization of all MV isolates through genetic 
study. This is because genetic study can identify source 
and transmission pathway of wild type (wt) MVs; thereby 
elucidating local virus transmission and or importation (Lo 
et al., 2001). Identification of wt MV in any country had 
necessitated epidemiological investigation and measles 
vaccination if wt virus was identified. A wide genetic 
diversity between indigenous wt MVs indicates whether 
or not measles vaccination was able to interrupt local 
transmission of the virus. Importantly, most study pro-
vides genetic characteristics and distribution  of  wild-type  




measles virus circulating in a country. In addition, the 
genetic study may reveal presence of some genotypes 
reportedly inactive. These include the B1, D1, E, F and 
G1 (Riddell et al., 2005). The mutation rate amongst field 
isolates of measles virus has been reported to be low and 
appear to be random rather than driven by vaccine 
pressure or immune responses (Rima et al., 1997). It has 
been considered significant that studies show the effect 
of mass vaccination on evolution of the virus in the vacci-
nation era in developing countries like Nigeria. It is 
important to genetically differentiate between wt and 
vaccine viruses associated with measles cases or out-
breaks. Recent studies have allowed observation of 
changes in MV genotypes over time in Nigeria to be 
made. Clarification of epidemiological links during mea-
sles outbreaks and separation of indigenous strains from 
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